Compare Duolingo Inc (DUOL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duolingo Inc vs Incyte Corporation — how do they compare? Duolingo Inc trades at $131.87 (market cap $6.34B), while Incyte Corporation trades at $120.54 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 3.9× Duolingo Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals.
| DUOL | INCY | |
|---|---|---|
Market Cap | $6.34B | $24.54B |
Sector | Technology | Health |
52-Week High | $369.19 | $129.93 |
52-Week Low | $90.03 | $81.61 |
Enterprise Value | $5.11B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duolingo trades at $131.94, down 3.83% amid mixed signals. The stock shows strong fundamentals with revenue growing from $369M in 2022 to $1.04B in 2025 and net income turning positive to $414M. Technical indicators show a bullish moving average trend but neutral oscillators, with key support at $129. Recent Q2 2026 earnings beat expectations with $0.66 EPS versus $0.604 expected, though Q3 revenue guidance disappointed investors.
The outlook remains cautiously optimistic with 30% analyst buy ratings but significant execution risk. Growth investments pressure near-term margins while user engagement strengthens. Key risks include monetization challenges and competitive threats in the edtech space. The consensus price target of $121 suggests limited upside from current levels.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duolingo Inc
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
